Page last updated: 2024-08-18

pyrroles and mitotane

pyrroles has been researched along with mitotane in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schein, PS1
Bang, SM; Kim, CJ; Kim, H; Kim, JH; Kim, JS; Kim, YJ; Lee, HE; Lee, JO; Lee, JS; Lee, KW1
Gelderblom, H; Guchelaar, HJ; Hartigh, Jd; Ploeger, BA; Romijn, JA; van Erp, NP1
Allolio, B; Fassnacht, M; Kroiss, M; Lutz, WK; Quinkler, M1
Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Lankheet, N; Laubner, K; Müller, HH; Pöllinger, A; Quinkler, M; Strasburger, CJ; van Erp, NP1
Chen, Y; Qiu, S; Tu, X; Wang, D; Wu, R; Zhuang, J1

Reviews

2 review(s) available for pyrroles and mitotane

ArticleYear
Chemotherapeutic management of the hormone-secreting endocrine malignancies.
    Cancer, 1972, Volume: 30, Issue:6

    Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Aminoglutethimide; Aniline Compounds; Antibiotics, Antineoplastic; Antineoplastic Agents; Butanones; Carcinoid Tumor; Diazoxide; Humans; Hypoglycemia; Insulin Antagonists; Kidney Tubules; Metyrapone; Mitotane; Neoplasm Metastasis; Pheochromocytoma; Pyrimidines; Pyrroles; Pyrrolidines; Ribonucleosides; Serotonin Antagonists; Streptozocin

1972
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
    Clinical endocrinology, 2011, Volume: 75, Issue:5

    Topics: Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Indoles; Mitotane; Pyrroles; Sunitinib

2011

Trials

2 trial(s) available for pyrroles and mitotane

ArticleYear
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
    European journal of endocrinology, 2011, Volume: 164, Issue:4

    Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activation; Female; Humans; Indoles; Male; Middle Aged; Mitotane; Pyrroles; Sunitinib

2011
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Disease Progression; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Middle Aged; Mitotane; Pyrroles; Sunitinib; Treatment Outcome; Young Adult

2012

Other Studies

2 other study(ies) available for pyrroles and mitotane

ArticleYear
Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:3

    Topics: Adrenal Cortex Neoplasms; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Resistance, Neoplasm; Humans; Indoles; Male; Mitotane; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Treatment Failure; Treatment Outcome; Young Adult

2009
Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:11

    Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Humans; Indoles; Lung Neoplasms; Mitotane; Multiple Pulmonary Nodules; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed

2015